

Curriculum Vitae

Personal information Gwenaëlle Veyrac

Work experience

- Employer: hospital
 - Start date: 1990
 - End date:
 - Position: MD
 - Activities:
- Pharmacologist
- Pharmacovigilance
- Spontaneous reporting systems and database
- Country: France

Education and training

- Subject: biology institute
 - Start date:
 - End date:
 - Qualification: pharmacologist
 - Organisation:
 - Country: France

Additional information

Publications

Publications Internationales 1_ P. JOLLIET, G. VEYRAC, M. BOURIN. First report of mirtazapine _induced arthralgie. Eur Psychiatry 2001 ; 16 : 1_3 2_ O. LAMBERT, G. VEYRAC, C. ARMAND et al. A lamotrigine _induced neutropenia with an equivalent of positive reintroduction. Adv Drug React Toxicol Rev. 2002, 21 : 157_159 3_ G. VEYRAC, P. JOLLIET. Urticaire médicamenteuse et imputabilité. Rev Fr Allergol Immunol Clin 2006; 46 : 283_7 4_ C. VICTORRI_VIGNEAU, E.DAILLY, G.VEYRAC, P.JOLLIET. Evidence of zolpidem abuse and dependence : results of the French Center for Evaluation and Information on Pharmacodependance (CEIP) network survey. Br J Clin Pharmacol 2007; 64,2 : 198_209 5_ P. JOLLIET, S. NION, G. ALLAIN_VEYRAC, L. TILLOY_FENART, D. VANUXEEM, V. BEREZOWSKI, R. CECHELLI. Evidence of lowest brain penetration of an antiemetic drug, metopimazine, compared to domperidone, metoclopramide and chlorpromazine, using and in vitro model of the Blood_Brain Barrier. Pharmacol Res 2007; 56 : 11_7 6_ M. GERARDIN_MARAIS, C. VICTORRI_VIGNEAU, G. ALLAIN_VEYRAC, A. CHASLERIE, M. NICOLAS, N. SARRAF, J. PIVETTE, P. JOLLIET. Diuretic Drugs Use in the Elderly: Which Monitoring? Eur J Clin Pharmacol 2008; 64 : 433_7 7_ C. CAILLET, G. DURRIEU, A. JACQUET and French Network of Pharmacovigilance Centres (G. VEYRAC). Safety surveillance of influenza A(H1N1)v monovalent vaccines during the 2009_2010 mass vaccination campaign in France. Eur J Clin Pharmacol 2011; 67 : 649_651 8_ G.ALLAIN_VEYRAC, A.LEBRETON, C.COLLONNIER, P.JOLLIET. First case of symmetrical drug _related intertriginous and flexural exanthema due to rivastigmine ? Am J Clin Dermatol 2011; 12,3 : 210_213 9_ G. DURRIEU, C. CAILLET, I. LACROIX, A. JACQUET, A. FAUCHER, S. OUARET, A. SOMMET, M_C PERAULT_POCHAT, C. KREFT_JAIS, A. CASTOT, C. DAMASE_MICHEL, J_L. MONTASTRUC et le réseau français des centres de pharmacovigilance (CPRV Nantes, G. VEYRAC) Campagne nationale de vaccination contre la grippe A (H1N1)v : suivi national de pharmacovigilance. Therapie 2011 ; 66, 6 : 527_54 10_ A. PIPET, G. VEYRAC, F. WESSEL, P. JOLLIET, A. MAGNAN, P. DEMOLY and P.J. BOUSQUET. A statement on cefazolin immediate hypersensitivity : data from a large database, and focus on the cross_reactivities. Clin Exp Allergy. 2011 ; 41 : 1602_8 11_ G. DURRIEU, A. PALMARO, L. POURCEL et al (G. VEYRAC pour CRPV Nantes). First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines : a comparison of reports submitted by patients and healthcare professionals. Drug Saf 2012, 35 ; 10 : 845_54 12_ C. JOYAU, G. VEYRAC, V. DIXNEUF, P. JOLLIET. Anti tumor necrosis factor alpha therapy and increased risk of de novo psoriasis ; is it really a paradoxical side effect ? Clin Expert Rheumatol 2012 ; 30 : 700_6 13_ F. CHAVANT, I. INGRAND, A.P. JONVILLE_BERA, C. PLAZANET, V. GRAS_CHAMPEL, L. LAGARCE, M. ZENUT, A. DISSON_DAUTRICHE, S. LOGEROT, M. AUFFRET, A. COUBRET_DUMAS, M.L. BRUEL, M. BOYER, M.A. BOS_THOMPSON, G. VEYRAC, P. CARLIER, M.N. BEYENS, S. LATES, C. DAMASE_MICHEL, A. CASTOT, C. KREFT_JAIS, M.C. PERAULT_POCHAT. The PREGVAXGRIP study : a cohort study to assess foetal and neonatal consequences of in utero exposure to vaccination against A (H1N1) v2009 influenza. Drug Saf 2013; 36 : 455_65 14_ M. REITTER, N. PETITPAIN, C. LATARCHE, J. COTTIN, N. MASSY, P. DEMOLY, P. GILLET, P.M. MERTES, the French Network of Regional Pharmacovigilance centres (G. VEYRAC citée). Fatal anaphylaxis with neuromuscular blocking agents: a risk factor and management analysis. Allergy 2014, 69 ; 954_9 15_ G. MOULIS, H. BAGHERI, L. SAILLER, AP. JONVILLE_BERA, E. WEBER, C. GUY, N. PETITPAIN, ML. LAROCHE, S. FAVRELIÈRE, J. BÉNÉ, B. BALDIN, L. VILLEVAL_FEDERICI, M. TEBACHER_ALT, V. BRES, G. VEYRAC, A. GRANDVUILLEMIN, C. MAUPRIVEZ, M. LAPEYRE_MESTRE, JL. MONTASTRUC, French Association of Pharmacovigilance Centers. Are adverse drug reaction patterns different between romoplostim and eltrombopag? 2009_2013 French Pharmacovigilance assessment. Eur J Intern Med 2014; 25 : 777_80 16_ D. DARNIS, G. VEYRAC, P. JOLLIET. The special case of diclofenac. Enliven Archive 2014 17_ L. GABORIAU, C. VICTORRI_VIGNEAU, M. GÉRARDIN, G. ALLAIN_VEYRAC, P. JOLLIET_EVIN, M. GRALL_BRONNEC. Aripiprazole : A new risk factor for pathological gambling? A report of 8 case reports. Addict Behav 2014; 39: 562_5 18_ S. HENNI, F. DELAMARRE_DAMIER, A. SONNIC, G. FEINARD, G. VEYRAC, JF; PUJOL, L. DE DECKER, G. BERRUT, S. PIESSEARD. NEURODEM : assessment of the iatrogenic alert indicator for nursing home patients with Alzheimer's of Alzheimer _like disease.Aging Clin Exp Res. 2015 ; 2015 Dec 6. [Epub ahead of print] 19_ D. DARNIS, J. MAHÉ, B.

VRIGNAUD, C. GRAS_LE GUEN, G.VEYRAC, P.JOLLIET. A report of adverse drug reactions in Pediatric Emergency Medicine. *Annals of Pharmacotherapy* 2015, Dec;49(12):1298_304 20. J. MAHE, D. DARNIS,G.VEYRAC, P.JOLLIET. Reply : Adverse Drug Reactions in Pediatric Emergency Medicine *Ann Pharmacother.* 2016 ;50(4): 332_333 21_ LE TURNIER P, BOUTOILLE D, JOYAU C, VEYRAC G, ASSERAY N. Bacterial infections and NSAIDs exposure? Seek septic complications. *European Journal of internal medicine.* 2017. 22_ DENIS PREVOT M, THILLARD EM, WALTHER J, VEYRAC G, LAROCHE ML, GAUTIER S, AUFFRET M. Pristinamycin_induced arthralgia and myalgia: Analysis of the French Pharmacovigilance Database. *Med Mal Infect.* 2017 Oct 28. pii: S0399_077X(16)30720_X. doi: 10.1016/j.medmal.2017.09.014. [Epub ahead of print]2017. 23_ LEBRUN_VIGNES B, GUY C, JEAN_PASTOR MJ, GRAS_CHAMPEL V, ZENUT M and The French Network of Regional Centres of Pharmacovigilance and the French Investigators for Adverse Skin Reactions to Drugss acetaminophen associated with a risk of Stevens-Johnson syndrome and toxic epidermal necrolysis? Analysis of the French Pharmacovigilance Database. *Br J Clin Pharmacol* 2018 Feb;84(2):331_338. doi: 10.1111/bcp.13445. Epub 2017 Nov 10. 24_ TOURILLON C, MAHÉ J, BARON A, LAMBERT A, YÉLEHÉ_OKOUMA M, VEYRAC G, JOLLIET P. Immediate_type hypersensitivity cross_reactions to proton pump inhibitors: A descriptive study of data from the French national pharmacovigilance database *Int Arch Allergy Immunol* 2018 25_ PETITPAIN N, ARGOUILLON L, MASMOUDI K, FEDRIZZI S, COTTIN J, LATARCHE C, MERTES P, GILLET P, FRENCH NETWORK OF REGIONAL PHARMACOVIGILANCE CENTRES (G VEYRAC COLLAB) (2018) Neuromuscular blocking agents induced anaphylaxis: Results and trends of a French pharmacovigilance survey from 2000 to 2012. *Allergy*, 73(11): 2224_33. 26_ Cloitre A, Duval X, Tubiana S, Giraud P, Veyrac G, Nosbaum A, Gouraud A, Mahé J, Lesclois P. Antibiotic prophylaxis for the prevention of infective endocarditis for dental procedures is not associated to fatal anaphylaxis and Clostridium difficile infections in France. *Med Oral Patol Oral Cir Bucal.* 2019 May 1;24 (3):e296_304. 27_ Hillaire_Buys D, Mousset M, Allouchery M, Azzouz B, Babin M, Bellet F, Béné J, Default A, Durrieu G, Géniaux H, Grandvilllemin A, Gras_Champel V, Jantzen H, Lambert A, Lepelletier M, Massy N, Petitpain N, Rocher F, Sanchez_Pena P, Sassier M, Simon C, Triquet L, Valnet_Rabier MB, Veyrac G, Faillie JL, Zenut MC. Liquid formulation of ifosfamide increased risk of encephalopathy: A case_control study in a pediatric population. *Thérapie.* 2019 Oct 28. PMID: 31732241. 28_ Soria A, Bernier C, Veyrac G, Barbaud A, Puymirat E, Milpied B. Drug reaction with eosinophilia and systemic symptoms (DRESS) may occur within two weeks of drug exposure: a retrospective study. *J Am Acad Dermatol.* 2019 Sep 25. PMID: 31562941. 29_ Gregoire M, Le Turnier P, Gaborit BJ, Veyrac G, Lecomte R, Boutoille D, Canet E, Imbert BM, Bellouard R, Raffi F. Lopinavir pharmacokinetics in COVID_19 patients [published online ahead of print, 2020 May 22]. *J Antimicrob Chemother.* 30_ Gouverneur A, Sanchez_Pena P, Veyrac G, Salem JE, Bégaud B, Bezin J. Neurocognitive Disorders Associated with PCSK9 Inhibitors: a Pharmacovigilance Disproportionality Analysis. *Cardiovasc Drugs Ther.* 2021 Aug 26. doi: 10.1007/s10557_021_07242_7. Online ahead of print. PMID: 34436707 _ Baudot J, Soeiro T, Tambon M, Navarro N, Veyrac G, Mezaache S, Micallef J. Safety concerns on the abuse potential of esketamine: Multidimensional analysis of a new anti_depressive drug on the market. *Fundam Clin Pharmacol.* 2022 Jun;36(3):572_581. doi: 10.1111/fcp.12745. Epub 2021 Dec 23. PMID: 34907579. Publications Nationales 1_ P. NETTER, Ph TRECHOT, G. ALLAIN et al. Le médecin français face à un effet inattendu. *Communications partenaires santé*, 1992, numéro spécial. 2_ A.CHIFFOLEAU, G. VEYRAC, S. BAUDOT et al. "Bilan de 2 années de suivi des questions "Médicaments _ Grossesse" au CRPV de Nantes". *Thérapie* 1995 ; 50 : 429_438. 3_ G. VEYRAC, A. CHIFFOLEAU, C. BAILLY et al. Hypertrichose chez un nourrisson d'une mère traitée par Minoxidil topique pendant les 6 derniers mois de grossesse. *Thérapie* 1995 ; 50 : 463_484. 4_ S. BEAUDOUIN, J. JACQUEMIN, A. CHIFFOLEAU, G. VEYRAC et al. Choc anaphylactique après une injection de morphine. *Thérapie* 1996 ; 51 : 191_196. 5_ C. LAROUSSE, A. CHIFFOLEAU, G. VEYRAC. Pharmacovigilance, Obligation légale ou obligation morale ? *Thérapeutiques*, avril 1999 ; 41. 6_ V. BRICARD_PACAUD, A. CHIFFOLEAU, G. VEYRAC et al. Frequency and cost evaluation of adverse drug reactions in a department of general medicine. *Thérapie* 1999 ; 54 : 282. 7_ N. ROUX_JEGOU, D. EL KOURI, JF CESARI, G. VEYRAC et al. Impact of iatrogenic effects on hospitalization in a department of general medicine : involvement of different health professionals. Poster. *Thérapie* 1999 ; 54 : 289. 8_ G. VEYRAC, A. CHIFFOLEAU, L. CELLERIN et al. Latanoprost (XALATAN®) et effet systémique respiratoire ? A propos d'un cas. *Thérapie* 1999 ; 54 : 494_496. 9_ C. LAROUSSE, A. CHIFFOLEAU, G. VEYRAC et al. Conditionnement : carton rouge. *La Revue Prescrire* 1999 ; 19 : 715. 10_ C. LAROUSSE, G. VEYRAC. Les inhibiteurs de COX_1 et COX_2, données cliniques = Quelles alertes possibles en Pharmacovigilance ? *Thérapie* 2000 ; 55 : 21_28. 11_ A.CHIFFOLEAU, D. YATIM, F. GARREC, G. VEYRAC et al. Warning ! a buflomedil may hide another ! *Thérapie* 2000 ; 55 : 221_223. 12_ N. ROUX_JEGOU, G. VEYRAC, R. CLEMENT et al. Méthotrexate à faibles doses et supplémentation en folates. *La Revue du Praticien _ Médecine Générale* 2000 ; 14 : 187_190. 13_ G. VEYRAC, B. GUILLON, N. THAJTE et al. Cerebral vasculitis and hemorrhage associated with phenylpropanolamine. *Thérapie* 2000 ; 55 : 410. 14_ A.CHIFFOLEAU, G. VEYRAC, V. ARGAIZ et al. First report of a possible interaction between acenocoumarol and topical treatment CYCLO 3®. *Thérapie* 2000 ; 55 : 411. 15_ G. VEYRAC, V. BRACHET, S. ROCHER et al. Mirtazapine (NORSET®) and arthralgia. *Thérapie* 2000 ; 55 : 422. 16_ G. VEYRAC, V. BRACHET, S. ROCHER et al. Arthralgies associées à la prise de Mirtazapine. *Thérapie* 2000 ; 55 : 652_655. 17_ G. VEYRAC, H. HUGUENIN, B. GUILLON et al. Hémorragies cérébrovasculaires et angiopathie cérébrale aiguë associées à la prise de phénylpropanolamine. Un nouveau cas. *Thérapie* 2001, 56 : 323_327. 18_ A.CHIFFOLEAU, H. HUGUENIN, G. VEYRAC et al. Interaction entre méliot et acénocoumarol ? (méliot_ruscus aculeatus). *Thérapie* 2001, 56 : 321_322. 19_ G. VEYRAC, M. PAULIN, B. MILPIED et al. Bilan de l'enquête nationale sur les effets indésirables cutanés du kétoprofène gel enregistrés entre le 01/09/1996 et le 31/08/2000. *Thérapie* 2002, 57 : 55_64. 20_ G. VEYRAC, A. CHIFFOLEAU, M. BOURIN et al. Photosensibilité exogène liée à la prise d'AINS sous forme topique. *La Lettre du pharmacologue* 2002, 16 : 161_166. 21_ A.CHIFFOLEAU, G. VEYRAC, C. BRUNET_FRANCOIS et al. Recueil systématique des effets indésirables des médicaments du VIH : Bilan de 18 mois de collaboration du CISIH et du CRPV. *La Lettre du Pharmacologue* 2002, 16, 123_129. 22_ A.ANGLES, H. BAGHERI, J.L. MONTASTRUC, J.F. MAGNAVAL + RESEAU DES CENTRES DE PHARMACOVIGILANCE. Pharmacovigilance des médicaments antipaludiques. Analyse de la notification spontanée en France (1996_2000). *La Presse Médicale* 2003, 32 : 106_113. 23_ G. VEYRAC, G. MARCADE, A. CHIFFOLEAU et al. Caractéristiques du syndrome d'hypersensibilité à la lamotrigine : revue à partir d'un cas observé au CRPV de Nantes. *Thérapie* 2002, 57 : 289_296. 24_ S. BOURLON, G. VEYRAC, C.ARMAND et al. Rhabdomyolyse sous rabéprazole (PARIET®), un inhibiteur de la pompe à protons. *Thérapie* 2003, 57 ; 6 : 597_600. 25_ A.CHIFFOLEAU, J.N. TROCHU, G. VEYRAC et al. Rhabdomyolyse liée à l'ajout du vérapamil à un traitement par simvastatine et ciclosporine chez un patient transplanté cardiaque. *Thérapie* 2003 ; 58 : 168_170. 26_ A.CHIFFOLEAU, G. VEYRAC, G. MIREMONT et al. Tramadol et anticoagulants oraux : Quel type d'interaction ? *Thérapie* 2003 ; 58 : 471_474. 27_ CHIFFOLEAU, D. DRUI, G. VEYRAC, J.M. CHALIGNY, B. MILPIED, P. JOLLIET. Urticaire cholinergique révélée par les □_bloquants. A propos d'un cas et de sa prise en charge thérapeutique. *Thérapie* 2005; 60 : 593_5. 28_ G. VEYRAC, L. CELLERIN, P. JOLLIET. Premier cas de pneumopathie interstitielle rapporté sous atorvastatine (TAHOR®) : Synthèse des cas publiés sous statines. *Thérapie* 2006; 61 : 57_67. 29_ M. GERARDIN_MARAIS, G. ALLAIN_VEYRAC, I. DANNER, P. JOLLIET. Lithiase biliaire et cholécystite au voriconazole (V_FEND®) – A propos de 3 cas nantais en 2004. *Thérapie* 2006; 61 : 367_9. 30_ VICTORRI_VIGNEAU, M. MARAIS, G. VEYRAC, A. CHASLERIE, J. PIVETTE, P. JOLLIET. Réactivité et communication des décisions de pharmacovigilance des autorités de santé vers les professionnels de santé : exemples du pergolide et du célécoxib. *Thérapie* 2007; 62 : 513_7. 31_ G. VEYRAC, A. LEBRETON, P. JOLLIET. Ostéonécroses de la mâchoire associées à la prise de biphosphonates. *La Lettre du Pharmacologue* 2009; 23 ,2 : 41_7. 32_ J.L. MONTASTRUC et coll (G. VEYRAC pour CRPV Nantes). Pharmacovigilance study of influenza A H1N1 vaccination during the 2009_2010 season in France. *Bull Acad Natl Med* 2011; 195, 6 : 1309_17. 33_ A.NEEL, M. SEVIN, E. AUFFRAY_CALVIER, G. VEYRAC, B. GUILLON, M. HAMIDOU. Médicaments vasoconstricteurs et syndrome de vasoconstriction cérébrale réversible : à propos de 22 cas. *La Revue de Médecine Interne* 2012; C0029 : A42. 34_ VICTORRI_VIGNEAU C, PAILLE C, JOYAU C, VEYRAC G, COSSET C, LE PELLETIER A, JOLLIET P, NIZARD J, KUHN E.MEOPA use practices in a university hospital: Which conformity? *Therapie* Dec;72(6):659_663. doi: 10.1016/j.therap.2017.04.003. Epub 2017 May 26.. 2017 35_ BERTHELOT JM, VEYRAC G. Arthralgies et arthrites d'origine médicamenteuses, rares ou émergentes. *Revue du rhumatisme* 2018. □

A reply, drug-induced reversible cerebral vasoconstriction syndrome: Lessons from the real world.

FAVRELIERE SYLVIE,MAHE JULIEN,**VEYRAC GWENAELE**,NEAU JEAN-PHILIPPE,LAFAY-CHEBASSIER CLAIRE

PERAULT MARIE-CHRISTINE. Cephalalgia 2025

Drug reaction with eosinophilia and systemic symptoms induced by paclitaxel, a rare combination.LAGASSY MATHIEU,BARTHELEMY MATHILDE,KIEFFER CAMILLE,BOULAY CHARLENE,**VEYRAC GWENAELLE** ;LEFEBVRE ALEXIS
TETART FLORENCE. Br J Clin Pharmacol 2025

Tchatat Wanguieu L, Sam-Lai NF, Allouchery M, **Veyrac G**, Aroux-Pavard M, Boulay C, Richard V, Massy N. Propofol infusion syndrome: Analysis of French pharmacovigilance and World Health Organization Pharmacovigilance (VigiBase®) databases from 2020 to 2023. Therapie. 2024 Apr 30:S0040-5957(24)00062-3. doi: 10.1016/j.therap.2024.04.005. Epub ahead of print. PMID: 38839464.

Bourneau-Martin D, Grandvullemin A, Babin M, Mullet C, Said H, Cellier M, Geniaux H, Gautier S, Beurrier M, **Veyrac G**, Lagarce L, Laroche ML, Briet M. Adverse drug effect in the context of drug shortage: the CIRUPT prospective study from the French pharmacovigilance network. Eur J Hosp Pharm. 2024 Apr 15:ejhpharm-2023-004047. doi: 10.1136/ehjpharm-2023-004047. Epub ahead of print. PMID: 38621957.

Immediate allergies to chlorhexidine: A series of pediatric cases from the French pharmacovigilance database: Immediate allergies to chlorhexidine: series of pediatric cases from the French pharmacovigilance database.FONTAINE CLAIRE, ROCHEFORT-MOREL CECILE,**VEYRAC GWENAELLE**,POLARD ELISABETH, SCAILTEUX LUCIE-MARIE
Arch Pediatr 2024

Clinical and radiological pattern of olaparib-induced interstitial lung disease.

BRUDON ALEXANDRE,FOURNIER DORINE,SELLE FREDERIC,SERONT EMMANUEL,**VEYRAC GWENAELLE**,ZALCMAN GERARD,GOUNANT VALERIE.BMC Pulm Med 2024

[Severe systemic vasculitis induced by ibrutinib].

FENOT M,WOAYE HUNE P,VIGOUROUX S,**VEYRAC G**,POIRAUD C. Rev Med Interne 2024

[Projects](#)

[Memberships](#)

[Other Relevant Information](#)